Treatment of rheumatoid arthritis with cytotoxic and antimetabolic drugs.
D000505:Alopecia / Q000139:chemically induced; D000630:Aminopterin / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001379:Azathioprine / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000139:chemically induced; D002699:Chlorambucil / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D003556:Cystitis / Q000139:chemically induced; D005260:Female; D006562:Herpes Zoster / Q000139:chemically induced; D006801:Humans; D007565:Jaundice / Q000139:chemically induced; D008466:Mechlorethamine / Q000627:therapeutic use; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use
D000963:Antimetabolites; D000970:Antineoplastic Agents; D002699:Chlorambucil; D008466:Mechlorethamine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D000630:Aminopterin; D001379:Azathioprine; D008727:Methotrexate